Remission of Recalcitrant Dermatomyositis Treated with Ruxolitinib

Myelofibrosis, with positivity for the JAK2 V617F mutation, developed in a patient with long-standing, poorly controlled dermatomyositis. When the myelofibrosis was treated with ruxolitinib, the dermatomyositis went into remission.